Quest Diagnostics Inc. (DGX): Price and Financial Metrics
DGX Price/Volume Stats
| Current price | $137.55 | 52-week high | $148.62 |
| Prev. close | $136.70 | 52-week low | $119.59 |
| Day low | $134.95 | Volume | 1,566,600 |
| Day high | $138.32 | Avg. volume | 1,064,316 |
| 50-day MA | $128.66 | Dividend yield | 2.21% |
| 200-day MA | $131.26 | Market Cap | 15.28B |
DGX Stock Price Chart Interactive Chart >
Quest Diagnostics Inc. (DGX) Company Bio
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe. (Source:Wikipedia)
Latest DGX News From Around the Web
Below are the latest news stories about QUEST DIAGNOSTICS INC that investors may wish to consider to help them evaluate DGX as an investment opportunity.
Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare ConferenceQuest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:45 p.m. Eastern Time. |
Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical OfficerQuest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that Yuri A. Fesko, M.D., has been named senior vice president and chief medical officer (CMO), effective immediately. |
Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test PanelQuest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic. |
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid ArthritisRelationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology SECAUCUS, NJ and WALTHAM, MA / ACCESSWIRE / December 19, 2023 / Quest Diagnostics (NYSE:DGX), the world's leading provider of ... |
Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test PanelQuest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives. Two of these classes are rapidly accelerating America's overdose crisis: other illi |
DGX Price Returns
| 1-mo | 6.74% |
| 3-mo | 5.45% |
| 6-mo | 8.30% |
| 1-year | -4.80% |
| 3-year | 9.78% |
| 5-year | 58.79% |
| YTD | 0.29% |
| 2023 | -10.05% |
| 2022 | -7.80% |
| 2021 | 47.86% |
| 2020 | 14.11% |
| 2019 | 31.13% |
DGX Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching DGX
Want to do more research on Quest Diagnostics Inc's stock and its price? Try the links below:Quest Diagnostics Inc (DGX) Stock Price | Nasdaq
Quest Diagnostics Inc (DGX) Stock Quote, History and News - Yahoo Finance
Quest Diagnostics Inc (DGX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...